pharma&
Pharma& is a prominent player in the pharmaceutical industry, headquartered in Austria (AT). Founded in 2018, the company has rapidly established itself as a leader in innovative healthcare solutions, focusing on areas such as drug development, clinical research, and regulatory affairs. With a commitment to enhancing patient outcomes, Pharma& offers a unique portfolio of services that streamline the drug approval process and optimise market access. Operating primarily in Europe, Pharma& has achieved significant milestones, including partnerships with leading healthcare organisations and successful product launches. Their expertise in navigating complex regulatory landscapes sets them apart, ensuring that clients receive tailored support throughout the pharmaceutical lifecycle. As a trusted partner in the industry, Pharma& continues to drive advancements in healthcare, solidifying its market position and reputation for excellence.
DitchCarbon Score
How does pharma&'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
pharma&'s score of 31 is higher than 71% of the industry. This can give you a sense of how well the company is doing compared to its peers.
pharma&'s reported carbon emissions
In 2023, pharma& reported total carbon emissions of approximately 48980 kg CO2e for Scope 1, 5240 kg CO2e for Scope 2, and about 477780 kg CO2e for Scope 3, bringing their total emissions to around 530000 kg CO2e. This marks a significant increase in Scope 1 emissions compared to 2022, where they were approximately 4510 kg CO2e, and a notable rise in Scope 3 emissions from about 228800 kg CO2e. In 2022, the company achieved a total of approximately 243410 kg CO2e across all scopes, indicating a fluctuating trend in their emissions profile. The data reveals that while Scope 1 and Scope 2 emissions have seen some variation, Scope 3 emissions have significantly increased, highlighting the challenges in managing indirect emissions. Despite these figures, pharma& has not disclosed any specific reduction targets or initiatives under the Science Based Targets initiative (SBTi) or other climate pledges. This lack of formal commitments suggests that while the company is tracking its emissions, it may need to establish clearer climate action strategies to address its carbon footprint effectively.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project| 2021 | 2022 | 2023 | |
|---|---|---|---|
| Scope 1 | 660,880 | 0,000 | 00,000 |
| Scope 2 | 97,000 | 00,000 | 0,000 |
| Scope 3 | 56,710 | 000,000 | 000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
pharma& is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
